Review article: Novel technologies in the treatment and monitoring of advanced and relapsed epithelial ovarian cancer.

Convergent science physical oncology Pub Date : 2017-01-01 Epub Date: 2017-02-23 DOI:10.1088/2057-1739/aa5cf1

Paula Cunnea, Sally Gowers, James E Moore, Emmanuel Drakakis, Martyn Boutelle, Christina Fotopoulou

{"title":"Review article: Novel technologies in the treatment and monitoring of advanced and relapsed epithelial ovarian cancer.","authors":"Paula Cunnea, Sally Gowers, James E Moore, Emmanuel Drakakis, Martyn Boutelle, Christina Fotopoulou","doi":"10.1088/2057-1739/aa5cf1","DOIUrl":null,"url":null,"abstract":"<p><p>Epithelial Ovarian cancer (EOC) is the fifth most common cause of cancer death in females in the UK. It has long been recognized to be a set of heterogeneous diseases, with high grade serous being the most common subtype. The majority of patients with EOC present at an advanced stage (FIGO III-IV), and have the largest risk for disease recurrence from which a high percentage will develop resistance to chemotherapy. Despite continual advances in diagnostics, imaging, surgery and treatment of EOC, there has been little variation in the survival rates for patients with EOC. In this review we will introduce novel bioengineering advances in modelling the lymphatic system and real-time tissue monitoring to improve the clinical and therapeutic outcome for patients with EOC. We discuss the advent of the non-invasive \"liquid biopsy\" in the surveillance of patients undergoing treatment and follow-up. Finally, we present new bioengineering advances for palliative care of patients to lessen symptoms of patients with ascites and improve quality of life.</p>","PeriodicalId":91466,"journal":{"name":"Convergent science physical oncology","volume":"3 ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2017-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1088/2057-1739/aa5cf1","citationCount":"2","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Convergent science physical oncology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1088/2057-1739/aa5cf1","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2017/2/23 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 2

Abstract

Epithelial Ovarian cancer (EOC) is the fifth most common cause of cancer death in females in the UK. It has long been recognized to be a set of heterogeneous diseases, with high grade serous being the most common subtype. The majority of patients with EOC present at an advanced stage (FIGO III-IV), and have the largest risk for disease recurrence from which a high percentage will develop resistance to chemotherapy. Despite continual advances in diagnostics, imaging, surgery and treatment of EOC, there has been little variation in the survival rates for patients with EOC. In this review we will introduce novel bioengineering advances in modelling the lymphatic system and real-time tissue monitoring to improve the clinical and therapeutic outcome for patients with EOC. We discuss the advent of the non-invasive "liquid biopsy" in the surveillance of patients undergoing treatment and follow-up. Finally, we present new bioengineering advances for palliative care of patients to lessen symptoms of patients with ascites and improve quality of life.

Abstract Image

查看原文本刊更多论文

综述文章:晚期和复发上皮性卵巢癌治疗和监测的新技术。

上皮性卵巢癌(EOC)是英国女性癌症死亡的第五大常见原因。长期以来，人们一直认为它是一组异质性疾病，高级别浆液是最常见的亚型。大多数EOC患者出现在晚期(FIGO III-IV)，并且疾病复发的风险最大，其中高比例的患者将对化疗产生耐药性。尽管在EOC的诊断、影像、手术和治疗方面不断取得进展，但EOC患者的生存率几乎没有变化。在这篇综述中，我们将介绍新的生物工程在淋巴系统建模和实时组织监测方面的进展，以改善EOC患者的临床和治疗结果。我们讨论非侵入性“液体活检”在接受治疗和随访的患者监测中的出现。最后，我们提出新的生物工程进展姑息治疗患者减轻症状的腹水患者和提高生活质量。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Convergent science physical oncology

自引率

0.00%

发文量